Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

dirkfrank Aug. 19 at 11:47 AM

$PRQR any reason for this sudden uptrend?

0 · Reply

cpratt25 Aug. 18 at 11:02 PM

@MS_Tammy Ever look at $PRQR ?

0 · Reply

struminbanjobio Aug. 18 at 9:45 PM

$PRQR 3ish range first resistance 4ish is next

0 · Reply

ehpats Aug. 18 at 9:02 PM

$PRQR I can see this easily going to $3-$4 range without much effort/resistance.

0 · Reply

JCLuckman Aug. 18 at 8:36 PM

$PRQR Fuse Lit! Buckle up! 🔥

0 · Reply

dirkfrank Aug. 18 at 8:20 PM

$PRQR tech gets some beating and this giant leaps up 🆙 in the air

2 · Reply

movnup Aug. 18 at 7:56 PM

$PRQR looking good! We could see a golden cross in a few days and then liftoff from there.

0 · Reply

Stockswingalert Aug. 18 at 7:36 PM

$PRQR Nhod $$$

0 · Reply

struminbanjobio Aug. 18 at 7:19 PM

$PRQR breakout to $3

0 · Reply

jacksparo Aug. 18 at 7:17 PM

$PRQR From July 26th email Paid almost 35% easy smooth swing . This stock among the easiest one to swing . Traded and shared in my different groups more than 20 times in the last 7 months.

2 · Reply

ProQR Announces Second Quarter 2026 Operating and Financial Results

Aug 13, 2026, 7:00 AM EDT - 6 days ago

ProQR Therapeutics Earnings release: Q2 2026

2026-07-06T20:15:23.000Z - 6 weeks ago

ProQR Therapeutics registers to sell 3.03M ordinary shares for holders

Jul 6, 2026, 8:00 AM EDT - 6 weeks ago

ProQR Therapeutics Registration statement: Registration filing

2026-06-26T11:35:19.000Z - 7 weeks ago

ProQR Therapeutics price target lowered to $10 from $14 at Raymond James

2026-06-26T08:40:08.000Z - 7 weeks ago

ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch

2026-06-26T00:55:07.000Z - 7 weeks ago

ProQR Therapeutics price target lowered to $3 from $4 at Chardan

Jun 25, 2026, 7:00 AM EDT - 7 weeks ago

ProQR Therapeutics Slides: Conference presentation

2026-06-25T10:40:22.000Z - 7 weeks ago

ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering

LLY

2026-06-25T10:35:33.000Z - 7 weeks ago

ProQR Therapeutics announces positive Phase 1 data for AX-0810

Jun 25, 2026, 6:35 AM EDT - 7 weeks ago

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

Jun 25, 2026, 6:25 AM EDT - 7 weeks ago

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

May 12, 2026, 7:00 AM EDT - 3 months ago

ProQR Announces First Quarter 2026 Operating and Financial Results

May 12, 2026, 7:00 AM EDT - 3 months ago

ProQR Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:00 AM EDT - 3 months ago

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

May 4, 2026, 8:00 AM EDT - 3 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

2026-04-08T20:45:41.000Z - 4 months ago

ProQR Therapeutics management to meet with Cantor Fitzgerald

2026-04-08T20:40:37.000Z - 4 months ago

ProQR Therapeutics management to meet with Oppenheimer

Apr 8, 2026, 4:00 PM EDT - 4 months ago

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

Apr 8, 2026, 10:00 AM EDT - 4 months ago

ProQR Therapeutics Transcript: Status update

Apr 8, 2026, 10:00 AM EDT - 4 months ago

ProQR Therapeutics Press release: Status update

Apr 8, 2026, 10:00 AM EDT - 4 months ago

ProQR Therapeutics Slides: Status update

Apr 8, 2026, 8:00 AM EDT - 4 months ago

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

Mar 25, 2026, 8:00 AM EDT - 5 months ago

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

2026-03-12T11:46:03.000Z - 5 months ago

ProQR Therapeutics assumed with an Outperform at Oppenheimer

2026-03-12T11:10:29.000Z - 5 months ago

ProQR Therapeutics reports FY25 EPS (EUR 0.40) vs (EUR 0.32) last year

Mar 12, 2026, 7:00 AM EDT - 5 months ago

ProQR Announces Year End 2025 Operating and Financial Results

Mar 12, 2026, 7:00 AM EDT - 5 months ago

ProQR Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

ProQR Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 3:25 PM EDT - 5 months ago

ProQR Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 3, 2026, 4:30 PM EST - 6 months ago

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

2026-02-19T15:50:54.000Z - 6 months ago

ProQR Therapeutics participates in a conf call hosted by Cantor Fitzgerald

2026-02-09T13:05:14.000Z - 6 months ago

ProQR Therapeutics directors Dinko Valerio, Alison Lawton to depart

Feb 9, 2026, 8:00 AM EST - 6 months ago

ProQR Announces Planned Changes to Board Composition

2026-01-08T13:15:17.000Z - 7 months ago

ProQR announces initial safety, PK data from Phase 1 trial of AX-0810

LLY

Jan 8, 2026, 8:00 AM EST - 7 months ago

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Dec 4, 2025, 8:20 AM EST - 9 months ago

ProQR Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 8:00 AM EST - 9 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 9:30 AM EST - 10 months ago

ProQR Therapeutics Earnings release: Q3 2025

2025-11-06T12:21:19.000Z - 10 months ago

ProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last year

Nov 6, 2025, 7:00 AM EST - 10 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 3, 2025, 10:00 AM EST - 10 months ago

ProQR Therapeutics Transcript: Study Update

Nov 3, 2025, 10:00 AM EST - 10 months ago

ProQR Therapeutics Press release: Study Update

Nov 3, 2025, 10:00 AM EST - 10 months ago

ProQR Therapeutics Slides: Study Update

Oct 21, 2025, 1:00 PM EDT - 10 months ago

ProQR Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

2025-10-20T12:05:08.000Z - 10 months ago

ProQR Therapeutics receives CTA authorization for AX-0810

Oct 20, 2025, 8:00 AM EDT - 10 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

2025-10-16T16:15:25.000Z - 10 months ago

ProQR Therapeutics management to meet with Citizens JMP

Oct 13, 2025, 8:30 AM EDT - 11 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 9:30 AM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q2 2025

2025-08-07T11:32:48.000Z - 1 year ago

ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year

2025-08-07T11:32:17.000Z - 1 year ago

ProQR Therapeutics sees cash runway into mid-2027

Aug 7, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

2025-07-11T18:15:22.000Z - 1 year ago

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

Jun 26, 2025, 4:30 PM EDT - 1 year ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

May 12, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 11:30 AM EDT - 1 year ago

ProQR Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q1 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 1 year ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Annual report: Q4 2024

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Press release: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

ProQR Therapeutics Registration statement: Registration Filing

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 11, 2024, 10:00 AM EST - 1 year ago

ProQR Therapeutics Transcript: AGM 2024

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Nov 7, 2024, 9:30 AM EST - 1 year ago

ProQR Therapeutics Earnings release: Q3 2024

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 2 years ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 30, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Registration statement: Registration Filing

Sep 17, 2024, 9:10 AM EDT - 2 years ago

ProQR Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:30 PM EDT - 2 years ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Aug 8, 2024, 7:21 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q2 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Transcript: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Press release: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Slides: Status Update

May 9, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces First Quarter 2024 Operating and Financial Results

May 9, 2024, 2:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q1 2024

Apr 23, 2024, 7:00 AM EDT - 2 years ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 2 years ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 2 years ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Annual report: Q4 2023

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q4 2023

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 3 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 7, 2023, 5:00 AM EST - 3 years ago

ProQR Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 7:00 AM EST - 3 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 3 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 3, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q2 2023

Aug 1, 2023, 7:00 AM EDT - 3 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 6, 2023, 7:00 AM EDT - 3 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

May 16, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q1 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Upcoming Investor Conferences in April and May

dirkfrank Aug. 19 at 11:47 AM

$PRQR any reason for this sudden uptrend?

0 · Reply

cpratt25 Aug. 18 at 11:02 PM

@MS_Tammy Ever look at $PRQR ?

0 · Reply

struminbanjobio Aug. 18 at 9:45 PM

$PRQR 3ish range first resistance 4ish is next

0 · Reply

ehpats Aug. 18 at 9:02 PM

$PRQR I can see this easily going to $3-$4 range without much effort/resistance.

0 · Reply

JCLuckman Aug. 18 at 8:36 PM

$PRQR Fuse Lit! Buckle up! 🔥

0 · Reply

dirkfrank Aug. 18 at 8:20 PM

$PRQR tech gets some beating and this giant leaps up 🆙 in the air

2 · Reply

movnup Aug. 18 at 7:56 PM

$PRQR looking good! We could see a golden cross in a few days and then liftoff from there.

0 · Reply

Stockswingalert Aug. 18 at 7:36 PM

$PRQR Nhod $$$

0 · Reply

struminbanjobio Aug. 18 at 7:19 PM

$PRQR breakout to $3

0 · Reply

jacksparo Aug. 18 at 7:17 PM

$PRQR From July 26th email Paid almost 35% easy smooth swing . This stock among the easiest one to swing . Traded and shared in my different groups more than 20 times in the last 7 months.

2 · Reply

JCLuckman Aug. 18 at 6:07 PM

$PRQR Last Call 🥃

0 · Reply

Stockswingalert Aug. 18 at 5:55 PM

$PRQR finally over $2 🔥👀 Hopefully lot more coming here if you look left

0 · Reply

FutureInvesting777 Aug. 18 at 5:38 PM

$PRQR well well well! The forbidden zone has been entered….

0 · Reply

vu_jade Aug. 18 at 4:13 PM

$PRQR insiders only buy for a dozen reasons! 😜

0 · Reply

Filvul Aug. 17 at 6:45 PM

$PRQR

0 · Reply

Valueforall Aug. 17 at 3:48 PM

$PRQR 🥂 to @johnnygogogo for the tip Watching $PRQR: Axiomer platform looks like a legit peer to Wave's PRISM. Edits RNA using endogenous ADAR, no DNA tinkering or viral vectors needed. Lilly co-sign: Eli Lilly deal brings cash and big-pharma validation while PRQR keeps full control of its owned pipeline. Beat-down valuation Small starter position: Asymmetric setup here. Cash and partner bio-bucks cushion the downside, and any positive early clinical data rerates this fast. Dipping a toe in here as a diversity play in a space I really like

0 · Reply

Akex1987ita Aug. 17 at 2:32 PM

$PRQR 17/8 H.C. Wainwright reiterates Buy and $12 PT on ProQR, citing AX-0810 as the key value driver and clinical data as validation of the Axiomer platform.

1 · Reply

movnup Aug. 17 at 1:41 PM

$PRQR keeps knocking on the $2 door and retreating. Patiently waiting for it to breakthrough that $2 ceiling and fly.

2 · Reply

dirkfrank Aug. 14 at 9:54 AM

$PRQR I’m thinking about closing my position. With a little loss. I don’t expect anything within the next 2-3 years. And that’s past my horizon for this venture.

3 · Reply

FutureInvesting777 Aug. 13 at 3:54 PM

$PRQR “Continue to execute on Lilly collaboration, with potential data updates and milestone payments.”

2 · Reply

ehpats Aug. 13 at 1:34 PM

$PRQR nothing from the lly front in this report. Lly seems to be incredibly patient. Years of investment and partnership deals with nothing but clinical work in return from Prqr. Some decent movement on this front would really bolster the PPS, but we get nothing.

1 · Reply

Geert07 Aug. 13 at 11:34 AM

$PRQR https://www.proqr.com/press-releases/proqr-announces-second-quarter-2026-operating-and-financial-results?utm_source=Newsletter&utm_medium=email&utm_campaign=PR_emailalerts

0 · Reply

Market Cap	203.35M
Revenue (ttm)	18.00M
Net Income (ttm)	-47.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-265.17%
Debt to Equity Ratio	0.06

Volume	1,554,600
Avg Vol	1,121,506
Day's Range	N/A - N/A
Shares Out	105.36M
Stochastic %K	97%
Beta	0.07
Analysts	Strong Sell
Price Target	$8.25